HomeCompareALRN vs EPRT

ALRN vs EPRT: Dividend Comparison 2026

ALRN yields 94.79% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALRN wins by $3.08M in total portfolio value
10 years
ALRN
ALRN
● Live price
94.79%
Share price
$2.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.14M
Annual income
$1,021,196.07
Full ALRN calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ALRN vs EPRT

📍 ALRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALRNEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALRN + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALRN pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALRN
Annual income on $10K today (after 15% tax)
$8,056.87/yr
After 10yr DRIP, annual income (after tax)
$868,016.66/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ALRN beats the other by $857,102.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALRN + EPRT for your $10,000?

ALRN: 50%EPRT: 50%
100% EPRT50/50100% ALRN
Portfolio after 10yr
$1.60M
Annual income
$517,018.39/yr
Blended yield
32.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ALRN
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Altman Z
-26.5
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALRN buys
0
EPRT buys
0
No recent congressional trades found for ALRN or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALRNEPRT
Forward yield94.79%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$3.14M$63.4K
Annual income after 10y$1,021,196.07$12,840.73
Total dividends collected$2.79M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ALRN vs EPRT ($10,000, DRIP)

YearALRN PortfolioALRN Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$20,179$9,478.67$11,205$505.18+$9.0KALRN
2$39,467$17,875.42$12,672$682.46+$26.8KALRN
3$74,904$32,674.56$14,490$930.48+$60.4KALRN
4$138,103$57,956.24$16,786$1,282.69+$121.3KALRN
5$247,636$99,865.76$19,753$1,791.56+$227.9KALRN
6$432,328$167,356.66$23,677$2,541.64+$408.7KALRN
7$735,650$273,059.80$29,008$3,672.99+$706.6KALRN
8$1,221,388$434,242.66$36,463$5,425.08+$1.18MALRN
9$1,980,686$673,800.19$47,238$8,221.57+$1.93MALRN
10$3,140,530$1,021,196.07$63,385$12,840.73+$3.08MALRN

ALRN vs EPRT: Complete Analysis 2026

ALRNStock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Full ALRN Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ALRN vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALRN vs SCHDALRN vs JEPIALRN vs OALRN vs KOALRN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.